Search - tctmd.com

Displaying 21 - 40 of 59

Sort: Relevancy | Date

Gatekeeper CTA Strategy in Stable Chest Pain Still Needs Honing

News Daily News

Gatekeeper CTA Strategy in Stable Chest Pain Still Needs Honing

Yael L. Maxwell

March 08, 2021

News Opinion Editor's Corner

The Biggest News of 2020: TCTMD’s Top 10

December 28, 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

News Conference News AHA 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

November 15, 2020

More Circulating Omega-3s May Boost Prognosis After STEMI

News Daily News

More Circulating Omega-3s May Boost Prognosis After STEMI

October 26, 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

October 21, 2020

TCT ID 3: Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention – Insights From REDUCE-IT PCI

Presentation TCT 2020

TCT ID 3: Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention – Insights From REDUCE-IT PCI

Presenter: Benjamin Peterson

October 15, 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

Reduction of Revascularization in Patients with Hypertriglyceridemia with Icosapent Ethyl: Insights from REDUCE-IT REVASC

Presentation SCAI 2020

Reduction of Revascularization in Patients with Hypertriglyceridemia with Icosapent Ethyl: Insights from REDUCE-IT REVASC

Presenter: Benjamin E. Peterson

May 21, 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

May 15, 2020

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

FDA Approves Icosapent Ethyl for Reducing CVD Events

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

News Daily News

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

November 25, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.